As of today (2024-05-24), Myomo's share price is $3.82.
Myomo's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.22. Hence, Myomo's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Myomo's Price-to-Free-Cash-Flow or its related term are showing as below:
MYO's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 33.705 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 57.20% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 59.50% per year.
During the past 8 years, Myomo's highest 3-Year average Free Cash Flow per Share Growth Rate was 60.20% per year. The lowest was -7.80% per year. And the median was 57.20% per year.
Myomo Price-to-Free-Cash-Flow Historical Data
The historical data trend for Myomo's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Myomo's Price-to-Free-Cash-Flow
For the Medical Devices subindustry, Myomo's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myomo's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Myomo's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Myomo's Price-to-Free-Cash-Flow falls into.
Myomo Price-to-Free-Cash-Flow Calculation
Myomo's Price-to-Free-Cash-Flow ratio for today is calculated as
Myomo's Share Price of today is $3.82. Myomo's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.22.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Myomo Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Myomo's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the device to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYO has been successfully added to your 